APR 21, 2019 09:19 PM PDT

Hypertensive Drug Could Treat An Array of Neurodegenerative Diseases

WRITTEN BY: Nouran Amin

In studies carried out on mice and zebrafish, a prescribed drug for hypertension may be promising for treating a collection of neurodegenerative diseases. Neurodegenerative diseases are a result of a build-up of misfolded proteins that cause 'aggregates' and result in irreversible damage to the nerve cells in the brain.

For healthy individuals, a build-up of proteins is resolved by autophagy--a mechanism used by the body that involves 'Pac-Man'-like cells that eradicate toxic materials. However, in neurodegenerative diseases, autophagy is impaired and thus, cannot clear the protein build-up in the brain.

The need to develop drugs that can induce autophagy effectively in neurodegenerative patients has been increasingly critical than ever. Such urgency has pushed scientists to look into re-purposing existing drugs. Drug re-purposing holds the advantage of having already been shown to be safe for use in humans which makes the process of clinical use much faster in the treatment of other targeted diseases.

Now, in a study published in Nature Communications, felodipine, a drug for the treatment of hypertension, may serve as a candidate for re-purposing in the treatment of neurodegenerative diseases. Specifically, felodipine has been shown to induce autophagy and could alleviate the symptoms of neurodegenerative disease.

Credit: University of Cambridge

In mice and zebrafish, felodipine was effective at decreasing the build-up of toxic aggregates in diseases like Huntington, Parkinson and dementia models.

"This is the first time that we're aware of that a study has shown that an approved drug can slow the build-up of harmful proteins in the brains of mice using doses aiming to mimic the concentrations of the drug seen in humans," says Professor David Rubinsztein. "As a result, the drug was able to slow down progression of these potentially devastating conditions and so we believe it should be trialled in patients."

"This is only the first stage, though. The drug will need to be tested in patients to see if it has the same effects in humans as it does in mice. We need to be cautious, but I would like to say we can be cautiously optimistic."

Source: University of Cambridge

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 06, 2019
Cell & Molecular Biology
JAN 06, 2019
An Inhalable Form of Messenger RNA Might be a New Kind of Therapeutic
Messenger RNA normally carries genetic information from the genome to the ribosome, but researchers want to use it to treat disease....
JAN 16, 2019
Genetics & Genomics
JAN 16, 2019
Gene Therapy for a Leading Cause of Infant Death is Closer to Market
New treatments for some diseases can have extremely high price tags. One example is Zolgensma, which might cost $5 million per patient....
MAR 10, 2019
Drug Discovery
MAR 10, 2019
Can Green Tea Reverse Memory Impairment?
In a study published in the Journal of Biological Chemistry, a diet containing green tea and carrots reversed Alzheimer's-like symptoms in mice that ar...
MAR 20, 2019
Drug Discovery
MAR 20, 2019
First Drug for Postpartum Depression
The U.S. Food and Drug Administration recently approved the first ever drug specifically for the treatment of postpartum depression a common and often deva...
MAR 31, 2019
Drug Discovery
MAR 31, 2019
Chemopreventative Drug Targets H. Pylori Infections
A chemopreventative drug being tested for its ability to inhibit the production of cell growth in multiple types of cancer was found to act directly on the...
MAY 07, 2019
Microbiology
MAY 07, 2019
Disrupting tRNA in Bacteria - A Way to Fight Antibiotic Resistant Microbes
Antibiotic-resistant bacteria already cause the deaths of around 23,000 people every year, and that number is expected to rise dramatically....
Loading Comments...